Alpha Cognition rises on commercial launch of Alzheimer's drug

Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91

ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease (AD)

Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people

Co says patients can now access the drug in 5 milligram (mg), 10 mg and 15 mg doses

Zunveyl was approved by the FDA to treat AD in July 2024

Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s

As of last close, ACOG down ~65% in the past 12 months